PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022
London (PRWEB) November 04, 2013 -- PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022
Summary
Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.
The Indian NSCLC market has been especially difficult for drug companies to penetrate, and the market revolves almost exclusively around generics. The market is dominated by generic chemotherapies including pemetrexed (Alimta) as well as the generic targeted therapies erlotinib (Tarceva) and gefitinib (Iressa).
Scope
-Overview of NSCLC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
-Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
-Sales forecast for the top drugs in India from 2012-2022.
-Analysis of the impact of key events as well the drivers and restraints affecting India NSCLC market.
Reasons to buy
-Understand and capitalize by identifying products that are most likely to ensure a robust return
-Stay ahead of the competition by understanding the changing competitive landscape for NSCLC
-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
-Make more informed business decisions from insightful and in-depth analysis of drug performance
-Obtain sales forecast for drugs from 2012-2022 in India.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology and Histology 13
3.1.3 NSCLC Biomarkers 14
3.1.4 Quality of Life 15
3.2 Symptoms 16
4 Disease Management 18
4.1 Treatment Overview 18
4.1.1 Diagnosis 19
4.1.2 Clinical Staging 20
4.1.3 Screening and Early Detection 22
4.1.4 Localized Procedures and Therapies 23
4.1.5 Systemic Chemotherapy 24
4.1.6 Targeted Therapy 25
4.2 India 27
4.2.1 Diagnosis 27
4.2.2 Clinical Practice 28
5 Competitive Assessment 30
5.1 Overview 30
5.2 Strategic Competitor Assessment 31
5.3 Product Profiles – Major Brands, Chemotherapies 33
5.3.1 Alimta (pemetrexed disodium) 33
5.4 Product Profiles – Major Brands, Targeted Therapies 37
5.4.1 Iressa (gefitinib) 37
5.4.2 Tarceva (erlotinib hydrochloride) 42
5.4.3 Xalkori (crizotinib) 48
5.4.4 Avastin (bevacizumab) 52
6 Opportunity and Unmet Need 56
6.1 Overview 56
6.2 Improved Overall Survival and Less Toxicity 57
6.3 Treatments for Patients with Acquired TKI Resistance 58
6.4 Better Treatment Options for Squamous Patients 59
6.5 Preventing Relapse or Recurrence 59
6.6 More Efficacious Second-Line Therapies 60
6.7 Increased Availability of Mutation Testing 60
6.8 More Cost-Effective Therapies 61
6.9 Unmet Needs Gap Analysis 62
7 Pipeline Assessment 66
7.1 Overview 66
7.2 Promising Drugs in Clinical Development 66
7.2.1 nintedanib (BIBF1120) 70
7.2.2 Gilotrif (afatinib) 74
7.2.3 dacomitinib (PF-00299804) 80
7.2.4 LDK378 84
8 Market Outlook 90
8.1 India 90
8.1.1 Forecast 90
8.1.2 Key Events 94
8.1.3 Drivers and Barriers 94
9 Appendix 96
9.1 Bibliography 96
9.2 Abbreviations 108
9.3 Methodology 112
9.4 Forecasting Methodology 112
9.4.1 Number of NSCLC Patients Currently Seeking Treatment 112
9.4.2 Percent Drug-treated Patients 113
9.4.3 Drugs Included in Each Therapeutic Class 113
9.4.4 Launch and Patent Expiry Dates 114
9.4.5 General Pricing Assumptions 114
9.4.6 Individual Drug Assumptions 117
9.4.7 Generic Erosion 121
9.4.8 Pricing of Pipeline Agents 122
9.5 Physicians and Specialists Included in This Study 124
9.6 Survey of Prescribing Physicians 126
9.7 About the Authors 127
9.7.1 Authors 127
9.7.2 Epidemiologists 128
9.7.3 Global Head of Healthcare 129
9.8 About GlobalData 130
9.9 Disclaimer 130
1.1 List of Tables
Table 1: Symptoms of Disease NSCLC 17
Table 2: Treatment Guidelines for NSCLC 19
Table 3: Stage Definitions for NSCLC 21
Table 4: Treatment Overview by Stage of Diagnosis for NSCLC 27
Table 5: Leading Treatments for NSCLC 33
Table 6: Product Profile – Alimta (pemetrexed disodium) 35
Table 7: Alimta SWOT Analysis, 2013 37
Table 8: Product Profile – Iressa (gefitinib) 39
Table 9: Iressa SWOT Analysis, 2013 42
Table 10: Product Profile – Tarceva (erlotinib hydrochloride) 44
Table 11: Tarceva SWOT Analysis, 2013 47
Table 12: Product Profile – Xalkori (crizotinib) 49
Table 13: Xalkori SWOT Analysis, 2013 52
Table 14: Product Profile – Avastin (bevacizumab) 53
Table 15: Avastin SWOT Analysis, 2013 55
Table 16: Overall Unmet Needs – Current Level of Attainment 57
Table 17: Clinical Unmet Needs – Gap Analysis, 2013 63
Table 18: Non-Small Cell Lung Cancer – Phase I-II Pipeline, 2013 67
Table 19: NSCLC – Phase III Pipeline, 2013 68
Table 20: NSCLC – Advantages and Disadvantages of Therapeutic Classes 69
Table 21: Product Profile – nintedanib (BIBF-1120) 70
Table 22: nintedanib SWOT Analysis, 2013 74
Table 23: Product Profile – Gilotrif (afatinib) 75
Table 24: Gilotrif SWOT Analysis, 2013 79
Table 25: Product Profile – dacomitinib (PF-00299804) 80
Table 26: dacomitinib SWOT Analysis, 2013 84
Table 27: Product Profile – LDK378 85
Table 28: LDK378 SWOT Analysis, 2013 89
Table 29: Sales Forecasts ($m) for NSCLC in India, 2012-2022 92
Table 30: Key Events Impacting Sales for NSCLC in India, 2012–2022 94
Table 31: NSCLC Market in India – Drivers and Barriers, 2012–2022 94
Table 32: Five Year Prevalence 113
Table 33: Key Launch Dates 114
Table 34: Physicians Surveyed by Country 126
1.2 List of Figures
Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 2012–2022 69
Figure 2: Sales for NSCLC in India by Drug, 2012–2022 93
Read the full report:
PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com
Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]
Share this article